BioMarin Pharmaceutical Files Current Report

Ticker: BMRN · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1048477

Biomarin Pharmaceutical INC 8-K Filing Summary
FieldDetail
CompanyBiomarin Pharmaceutical INC (BMRN)
Form Type8-K
Filed DateDec 22, 2025
Risk Levellow
Pages1
Reading Time2 min
Key Dollar Amounts$0.001 B
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, current-report, other-events

Related Tickers: BMRN

TL;DR

BioMarin filed a routine 8-K on 12/19/25 for 'Other Events'.

AI Summary

On December 19, 2025, BioMarin Pharmaceutical Inc. filed an 8-K report. The filing indicates that the report is a "Current Report" and is being filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The report's earliest event date is December 19, 2025, and it is categorized under "Other Events."

Why It Matters

This filing signifies a routine update or disclosure from BioMarin Pharmaceutical Inc. to the SEC, providing transparency to investors about company events.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for 'Other Events' and does not appear to contain material non-public information that would immediately impact the stock price.

Key Numbers

Key Players & Entities

FAQ

What specific event triggered this 8-K filing?

The filing is categorized under 'Other Events' and does not specify a particular event in the provided text.

What is the earliest date associated with this report?

The earliest event reported is dated December 19, 2025.

What is BioMarin Pharmaceutical Inc.'s Standard Industrial Classification code?

The SIC code listed is 2834, which corresponds to Pharmaceutical Preparations.

Where are BioMarin Pharmaceutical Inc.'s principal executive offices located?

The principal executive offices are located at 770 Lindaro Street, San Rafael, California, 94901.

What is the purpose of filing a Form 8-K?

A Form 8-K is a report of unscheduled material events or corporate changes that could be of importance to investors.

Filing Stats: 387 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-12-22 09:00:13

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. BioMarin Pharmaceutical Inc., a Delaware corporation Date: December 22, 2025 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing